Dicot Pharma Presents Q3 2026 Interim Report
Dicot Pharma says it has presented its Q3 2026 interim report and invites readers to a webcast.
Related stories
China Nuclear Engineering Q3 Net Profit Falls 27.68% YoY
M impact | EQUITY | Oct 29, 2026, 01:58 PM UTC
Mexican Exchange Suspends Trading in José Cuervo Shares
M impact | EQUITY | Oct 29, 2026, 01:52 PM UTC
Teck Resources Q3 2026 Profit Before Taxes Rises to $2.3 Billion
M impact | EQUITY | Oct 29, 2026, 01:52 PM UTC
Trent Names Bahram Vakil Chairman as Noel Tata Steps Down
Trent said Noel Tata will step down as chairman and director effective November 11. Bahram Vakil will succeed him, and Tata will become Chairman Emeritus from November 12.
L impact | EQUITY | Oct 29, 2026, 01:51 PM UTC
China Longyuan to Acquire Remaining Stake in Guangdong Guoneng Longyuan
China Longyuan will acquire the remaining stake in Guangdong Guoneng Longyuan.
M impact | EQUITY | Oct 29, 2026, 01:51 PM UTC
Jose Cuervo shares deepen losses, down 14%
M impact | EQUITY | Oct 29, 2026, 01:51 PM UTC